Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Integrilin for acute pain episodes in sickle cell disease
NCT00834899Phase 2Terminated
- Sponsor
- University of North Carolina at Chapel Hill
- Start
- Jan 2009
- Primary completion
- Mar 2012
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of eptifibatide in sickle cell disease (SCD), sponsored by University of North Carolina at Chapel Hill. Primary endpoint: Major Bleeding Episodes at 35 days. Started Jan 2009; status: terminated.
02
Drugs
eptifibatide
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT00834899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00834899.